Daito Pharmaceutical Co.,Ltd.
Financial Summary “Japan GAAP” (Consolidated) For the Fiscal Year Ended May 2026
Discloses full-year figures such as net sales. For the consolidated results for the fiscal year ending May 2026, YoY comparisons for revenue and profit items are provided, as well as major items from the balance sheet and income statement, and accompanying breakdowns of cash flows and asset composition. Future outlook is organized within the materials, enabling investors to review trends in revenue/profit and financial soundness.
Key Figures
- Net sales: 50,650 million yen
- Gross profit: 40,753 million yen
- Total net assets: 52,067 million yen
AI要約
Overview of Results
This Financial Summary (Japan GAAP, consolidated) reports the full-year results for the fiscal year ending May 2026, disclosing trends in various profit indicators centered on net sales. It includes the overseas business revenue composition, trends in materials costs, manufacturing costs, and selling, general and administrative expenses, along with segment-by-segment breakdowns including the pharmaceutical segment.
Financial Position and Outlook
The consolidated financial statements include the composition of assets and liabilities, cash and cash equivalents, and statements of cash flows, with financial indicators such as long-term borrowings also presented. The Financial Summary also contains an outline of future prospects and risk factors, and describes measures to adapt to changes in the business environment.
Daito Co., Ltd. (Stock: 4577)
Company overview · Stock price · Financial data · All IR
